Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors.
Podcast episode with expert insights on new data from WCLC 2020 helping to improve outcomes for patients with early-stage lung cancer, from Clinical Care Options (CCO)
Get expert insights from Clinical Care Options (CCO) on how to talk to your patients with lung or thyroid cancer about precision medicine
In this slideset from Clinical Care Options (CCO), Joel W. Neal, MD, PhD discusses antibody-drug conjugates within the clinical trial setting in NSCLC
Downloadable slideset with key highlight data from the 2020 WCLC Virtual Symposium from Clinical Care Options (CCO)